Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Authors: Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim G.J.V. Aerts, S. Cedrés, Alessandra Bearz, Kristiaan Nackaerts, Dean A. Fennell, Dariusz M. Kowalski, Anne S. Tsao, Paul Taylor, Federica Grosso, Scott Antonia, Anna K. Nowak, Maria Taboada, M. Puglisi, Paul K. Stockman, Hedy L. Kindler - The Lancet 2017 cited by 424